About Compass Therapeutics (CMPX)

Compass Therapeutics Inc (CMPX) is a biotechnology company that focuses on the discovery and development of antibody therapeutics to treat various diseases. The company utilizes its proprietary technology platform, known as the Compass Discovery Platform, to identify novel targets and develop antibodies that can modulate these targets. CMPX's approach is based on the principle that multiple antibodies targeting different epitopes on a target can provide improved therapeutic outcomes. The company has a diverse pipeline of antibody programs targeting different indications, including oncology and immunology. CMPX's lead candidate, CTX-471, is an investigational antibody targeting the inhibitory receptor PD-1, which is being evaluated in Phase 1 clinical trials for the treatment of advanced malignancies. The company also has collaborations with several pharmaceutical companies to develop antibody therapeutics for different diseases.

Compass Therapeutics Inc (CMPX) is listed on the stock exchange under the ticker symbol CMPX. As of [Current Date], the stock price of CMPX is [Current Stock Price]. The stock has had a volatile price history, with fluctuations driven by various factors such as clinical trial results, regulatory updates, and market sentiment. It is important for investors to conduct thorough research and analysis before making investment decisions.